Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refractory B Cell NHL

NCT05296525 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

13

Enrollment

INDUSTRY

Sponsor class

Stopped Study terminated by Sponsor.

Conditions

Non-Hodgkin Lymphoma

Interventions

DRUG: GDA-201

Sponsor

Gamida Cell ltd